Hepion Pharmaceuticals In... (HEPA)
0.48
-0.01 (-2.64%)
At close: Jan 14, 2025, 3:59 PM
0.48
-1.02%
After-hours Jan 14, 2025, 05:56 PM EST
undefined% (undefined)
| Bid | 0.47 |
| Market Cap | 3.34M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -4.4 |
| PE Ratio (ttm) | -0.11 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 0.63 |
| Volume | 37,509 |
| Avg. Volume (20D) | 59,762 |
| Open | 0.50 |
| Previous Close | 0.49 |
| Day's Range | 0.48 - 0.50 |
| 52-Week Range | 0.43 - 3.49 |
| Beta | undefined |
About HEPA
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 10, 2014
Employees 22
Stock Exchange NASDAQ
Ticker Symbol HEPA
Website https://www.hepionpharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for HEPA stock is "Hold." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
1 month ago ·
Source
-7.15%
Hepion Pharmaceuticals shares are trading lower. T...
Unlock content with
Pro Subscription
2 months ago ·
Source
+7.64%
Hepion Pharmaceuticals shares are trading higher after announcing SEC approval for its merger with Pharma Two B. The deal is expected to close in Q4 2024 pending shareholder and regulatory approvals.
